Treatment with epratuzumab 2400 mg cd was well tolerated in patients with moderately to severely active SLE, and associated with improvements in disease activity. Phase III studies are ongoing.
No takes yet. Share an insight, caveat, or question.
Wallace et al. (2013) studied this question.